Loes score 0.5-9
1 drugsPredictive biomarker for patient selection in 1 indication
1
Approved Drugs
1
Indications
1
Companies
Loes score 0.5-9 is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 1 indication including Cerebral Adrenoleukodystrophy. Explore the targeted therapies, indications, testing methods, and companies developing Loes score 0.5-9 drugs below.
Search Loes score 0.5-9 Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting Loes score 0.5-9
| Drug | Company | Therapeutic Area |
|---|---|---|
| Skysona | bluebird bio |
Loes score 0.5-9 Indications
Cerebral Adrenoleukodystrophy